Høyer-Hansen Group

All publications - 2001 to present

Bruyère F, Melen-Lamalle L, Blacher S, Detry B, Masset A, Lecomte J, Lambert V, Maillard C, Høyer-Hansen G, Lund LR, Foidart JM and Noël A:
Does plasminogen activator inhibitor-1 drive lymphangiogenesis?
PLoS One. 2010, 5:e9653.

Nielsen HJ, Christensen IJ and Brünner N:
A novel prognostic index in colorectal cancer defined by serum carcinoembryonic antigen and plasma tissue inhibitor of metalloproteinases-1.
Scand J Gastroenterol. 2010;45:200-7.

Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M; All Departments of Rheumatology in Denmark:
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
Arthritis Rheum. 2010;62:22-32.

Begum FD, Høgdall E, Christensen IJ, Kjaer SK, Blaakaer J, Christensen L and Høgdall C:
Serum tetranectin is a significant prognostic marker in ovarian cancer patients.
Acta Obstet Gynecol Scand. 2010; 89:190-8.

Aldulaymi B, Christensen IJ, Sölétormos G, Jess P, Nielsen SE, Brünner N and Nielsen HJ:
Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer.
Anticancer Res. 2010 ; 30:233-7.

Knudsen AL, Bülow S, Tomlinson I, Möslein G, Heinimann K and Christensen IJ:
Attenuated Familial Adenomatous Polyposis (AFAP) Results from an international collaborative study.
Colorectal Dis. 2010; Epub ahead of print.

Begum FD, Høgdall E, Christensen IJ, Christensen L, Kjaer SK, Blaakaer J, Petri AL and Høgdall C:
Serum tetranectin as a preoperative indicator for postoperative complications in Danish ovarian cancer patients.
Gynecol Oncol. 2010; 117:446-50.

Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthoej S, Carlsen N, Schmiegelow K and Peterson C:
The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number.
Blood. 2010; 115:4671-7.

Olson, F.J., Sørensen T.T., Ryndel, M., Høyer-Hansen, G. and Fagerberg, B.:
The soluble urokinase-type plasminogen activator receptor is associated with cardiovascular disease and risk factors in patients with symptomatic carotid atherosclerosis.
Clin. Biochem. 2010, 43:124-30.

Troelsen, L.N., Garred, P., Christiansen, B., Torp-Pedersen, C., Christensen, I.J., Narvestad, E. and Jacobsen, S.:
Double role of mannose-binding lectin in relation to carotid intima-media thickness in patients with rheumatoid arthritis.
Mol Immunol. 2010; 47: 713-8.

Morten G. Rasch, Ida K. Lund, Martin Illemann, Gunilla Høyer-Hansen, and Henrik Gårdsvoll:
Purification and characterization of recombinant full-length and protease-domain of murine MMP-9 in Drosophila S2 cells.
Protein Expression and Purification. 2010, 72: 87-94

Alpízar-Alpízar, W., Nielsen, B.S., Sierra, R., Illemann, M., Ramı´rez, J.A., Arias, A., Dura´n, S., Skarstein, A., Ovrebo, K., Lund, L.R. and Laerum, O.D.:
Urokinase plasminogen activator receptor is expressed in invasive cells in gastric carcinomas from high- and low-risk countries.
Int. J. Cancer. 2010, 126: 405–415.

Almasi, C.E., Høyer-Hansen, G., Christensen, I.J. and Pappot, H.:
Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer.
APMIS. 2009, 117: 755-61

Lomholt, A.F., Høyer-Hansen, G., Nielsen, H.J. and Christensen, I.J.:
Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.
Br J Cancer. 2009, 101: 992-7.

Klintman , M., Ornbjerg, W.S., Christensen, I.J., Bræmer, H.P., Fernö, M., Malmberg, M., Mouridsen, H., Cold, F., Schrohl, A.S., Foekens, J.A., Malmström, P. and Brünner, N.:
Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.
Breast Cancer Res Treat. 2009; 121:365-71.

Jensen, T.O., Schmidt, H., Møller, H.J., Høyer, M., Maniecki, M.B., Sjoegren, P., Christensen, I.J. and Steiniche, T.:
Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.
J Clin Oncol. 2009. 27: 3330-7.

Marquard, L., Poulsen, C.B., Gjerdrum, L.M., de Nully Brown, P., Christensen, I.J., Jensen, P.B., Sehested, M., Johansen, P. and Ralfkiaer, E.:
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Histopathology. 2009. 54: 688-98.

Frederiksen, C., Lomholt, A.F., Davis, G.J., Dowell, B.L., Blankenstein, M.A., Christensen, I.J., Brünner, N. and Nielsen, H.J.:
Changes in plasma TIMP-1 levels after resection for primary colorectal cancer.
Anticancer Res. 2009. 29: 75-81.

Larsen, J.M., Christensen, I.J., Nielsen, H.J., Hansen, U., Bjerregaard, B., Talts, J.F. and Larsson, L.I.:
Syncytin immunoreactivity in colorectal cancer: potential prognostic impact.
Cancer Lett. 2009. 280: 44-9.

Petri, A.L., Kjaer, S.K., Christensen, I.J., Blaakaer, J., Hogdall, E., Jeppesen, U., Mosgaard, B.J., Pagel, J.D., Stilling, L., Thranov, I. and Hogdall, C.:
Validation of epithelial ovarian cancer and fallopian tube cancer and ovarian borderline tumor data in the Danish Gynecological Cancer Database.
Acta Obstet Gynecol Scand. 2009.88: 536-42.

Begum, F.D., Høgdall, E., Kjaer, S.K., Blaakaer, J., Christensen, I.J., Christensen, L. and Høgdall, C.:
Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Gynecol Oncol. 2009. 113: 221-7.

Høgdall, E.V., Ringsholt, M., Høgdall, C.K., Christensen, I.J., Johansen, J.S., Kjaer, S.K., Blaakaer, J., Ostenfeld-Møller, L., Price, P.A. and Christensen, L.H.:
YKL-40 tissue expression and plasma levels in patients with ovarian cancer.
BMC Cancer. 2009. 9: 8.

Henic, E., Noskova, V., Høyer-Hansen, G., Hansson, S. and Casslén, B.:
Estradiol attenuates EGFnduced rapid uPAR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells. -i
Int J Gynecol Cancer. 2009, 19:214-22.

Alpízar-Alpízar, W., Laerum, O.D., Illemann, M., Ramírez, J.A., Arias, A., Malespín-Bendaña, W., Ramírez, V., Lund, L.R., Borregaard, N., Nielsen, B.S.:
Neutrophil gelatinase-associated lipocalin (NGAL/Lcn2) is upregulated in gastric mucosa infected with Helicobacter pylori.
Virchows Arch. 2009, 455:225–233.

Prager, G. W., Mihaly, J., Brünner, P.M., Koschelnick, Y., Høyer-Hansen, G. and Binder, B.:
Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein.
Blood. 2009, 113:1383-90.

Illemann, M., Bird, N., Majeed, A., Lærum, O.D., Lund, L.R., Danø, K. and Nielsen, B.S.:
Two Distinct Expession Patterns of Urokinase, Urokinase Receptor and Plasminogen Activator Inhibitor-1 in Colon Cancer Liver Metastases.
International Journal of Cancer. 2009, 124: 1860-1870.

Lund, I.K., Jögi, A., Rønø, B., Rasch, M.G., Lund, L.R., Almholt, K., Gårdsvoll, H., Behrendt, N., Rømer, J. and Høyer-Hansen, G.:
Antibody-mediated targeting of the uPA proteolytic function. Neutralizes fibrinolysis in vivo.
J.Biol. Chem. 2008, 283: 32506-15.

Frederiksen, C.B., Lomholt, A.F., Lottenburger, T., Davis, G.J., Dowell, B.L., Blankenstein, M.A., Christensen, I.J., Brünner, N. and Nielsen, H.J.:
Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1.
The International Journal of Biological Markers, 2008, 23: 42-47

Marquard, L., Gjerdrum, L.M., Christensen, I.J., Jensen, P.B., Sehested, M. and Ralfkiaer, E.:
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.
Histopathology. 2008, 53: 267-77.

Rasch, M.G., Pass, J., Illemann, M., Høyer-Hansen, G. and Lund, I.K.:
Discrimination of different forms of the murine urokinase receptor on the cell surface using monoclonal antibodies.
J. Immunol. Meth. 2008, 339: 55-65.

Henic, E., Borgfeldt, C., Christensen, I.J., Casslén, B. and Høyer-Hansen, G.:
Cleaved forms of the urokinase plasminogen activator receptor in plasma enhance discrimination of benign from malignant disease and predict survival in patients with ovarian cancer.
Clin. Cancer Res. 2008, 14: 5785-5793.

Christensen, I.J., Pappot, H. and Høyer-Hansen, G.:
The plasminogen activation system as a source of prognostic markers in cancer.
In The Cancer Degradome: Proteases and Cancer Biology. Eds. Edwards, D., Høyer-Hansen, G., Blasi, F., Sloane, B.F.
Springer, 2008, chapter 28.

Nielsen, B.S., Egeblad, M., Rank, F., Askautrud, H.A., Pennington, C.J., Pedersen, T.X., Christensen, I.J., Edwards, D.R., Werb, Z. and Lund, L.R.:
Matrix Metalloproteinase 13 is Induced in Fibroblasts in Polyoma Middle T Oncogenenduced Invasive Mammary Tumor, but Does Not Influence Progression.-i
PLoS ONE, 2008, 3: e2959 (1-11).

Schrohl, A.-S., Mueller, V., Christensen, I.J., Pantel, K., Thomssen, C. and Bruenner, N.:
A comparative study of Tissue Inhibitor of Metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.
Tumour Biol.. 2008, 29: 181-187.

Johansen, J.S., Lottenburger, T., Nielsen, H.J., Jensen, J.E.B., Svendsen, M.N., Kollerup, G. and Christensen, I.J.:
Diurnal, Weekly and Long Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects.
Cancer Epidemiol Biomarkers Prev. 2008, 17: 2603-8.

Iversen, L.H., Bülow, S., Christensen, I.J., Laurberg, S. and Harling, H.:
Postoperative medical complications are the main cause of early death after emergency surgery for colonic cancer.
British Journal of Surgery. 2008, 95: 1012–1019.

Petri, A.L., Høgdall, C., Christensen, I.J., Simonsen, A.H., T’Jampens, D., Hellmann, M.-L., Kjaer, S.K., Fung, E.T. and Høgdall, E.:
Sample handling for mass spectrometric proteomic investigations of human urine.
Proteomics Clin. Appl. 2008, 2: 184-1193.

Ytting, H., Christensen, I.J., Thiel, S., Jensenius, J.C. and Nielsen, H.J.:
Pre- and postoperative levels in serum of mannan-binding lectin associated serine protease-2 —a prognostic marker in colorectal cancer.
Human Immunology. 2008, 69:414–420.

Talman, M.L., Rasmussen, B.B., Andersen, J. and Christensen, I.J.:
Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications.
Acta. Oncol., 2008, 47:789-94.

Bülow, S., Bülow, C., Vasen, H., Järvinen, H., Björk, J., Christensen, I.J.:
Colectomy and Ileorectal Anastomosis is still an Option for Selected Patients with Familial Adenomatous Polyposis.
Dis Colon Rectum. 2008, 51: 1318-1323.

Laerum, O.D., Illemann, M., Skarstein, A., Helgeland, L., Øvfrebø, K., Danø, K. and Nielsen, B.S.:
Chrohn`s disease but not chronic ulcerative colitis induces the expression of PAI-1 in enteric neurons.
Am. J. Gastroenterology. 2008, 103: 2350-2358

Dejligbjerg, M., Grauslund, M., Christensen, I.J., Tjørnelund, J., Buhl Jensen, P., Sehested, M.:
Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines.
Cancer Biomark., 2008, 4: 101-9.

Nøjgaard, C., Høst, N.B., Christensen, I.J., Poulsen, S.H., Egstrup, K., Price, P.A., Johansen, J.S.:
Serum levels of YKL-40 increases in patients with acute myocardial infarction.
Coron Artery Dis., 2008, 19: 257-263.

Rasmussen, B.B., Andersson, M., Christensen, I.J., Møller, S.:
Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic variables.
Acta Oncol., 2008, 47: 784-8.

Sørensen, N.M., Schrohl, A.S., Jensen, V., Christensen, I.J., Nielsen, H.J., Brünner, N.:
Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
Scand. J. Gastroenterol, 2008, 43: 186-91.

Rasch MG, Lund IK, Almasi CE, Hoyer-Hansen G.:
Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer.
Front Biosci. 2008, 13: 6752-6762.

Knudsen, L.S., Chistensen, I.J., Lottenburger, T., Svendsen, M.N., Nielsen, H.J., Nielsen, L., Petersen, K.H., Jensen, J.E.B., Kollerup, G. & Johansen, J.S.:
Pre-Analytical and biological variability in circulating IL-6 in healthy subjects and patients with rheumatoid arthritis.
Biomarkers. 2008, 13:59-78.

Hansen, L.V., Lærum, O.D., Illemann, M., Nielsen, B.S., Ploug, M.:
Altered expression of the urokinase receptor homologue, C4.4A in invasive areas of human esophageal squamous cell carcinoma.
Int. J. Cancer. 2008, 122: 734-741.

Johansen, J.S., Brasso, K., Iversen, P., Teisner, B., Garnero, P., Price, P.A. & Christensen, I.J.:
Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival.
Clin Cancer Res. 2007,13: 3244-9.

Petri, A.L., Høgdall, E., Engelholm, S.A., Christensen, I.J., Kjaer, S.K.& Høgdall, C.K.:
Identification of new ovarian cancer biomarkers with proteomic analyses - the diagnostic tool of the future?
Ugeskr Laeger. 2007, 169: 2614-9.

Nielsen, B.S., Rank, F., Illemann, M., Lund, L.R. & Danø, K.:
Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ co-express urokinase and urokinase receptor.
Int. J. Cancer, 2007, 120: 2086-2095.

Madsen, D.H., Engelholm, L.H., Ingvarsen, S., Hillig, T., Wagenaar-Miller, R.A., Kjøller, L., Gårdsvoll, H., Høyer-Hansen, G., Holmbeck, K., Bugge, T.H., Behrendt, N.:
Extracellular collagenases and the endocytic receptor, uPARAP/Endo180, cooperate in fibroblast-mediated collagen degradation.
J. Biol. Chem., 2007. 282:27037-45.

Jögi, A., Pass, J., Høyer-Hansen, G, Lund, L.R., Nielsen B.S., Danø, K., Rømer, J.:
Systemic administration of anti-uPAR monoclonal antibodies induces hepatic fibrin deposition in tPA-deficient mice.
J Thromb Hæm. 2007, 5:1936-1944.

Pass, J., Jögi, A., Lund,I.K., Rønø, B., Rasch,M.G., Gårdsvoll,H., Lund, L.R., Ploug, M., Rømer, J., Danø, K., Høyer-Hansen, G.:
Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: Inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Thromb.Haem. 2007; 97:1013-22.

Ostrowski, S.R., Shulman, C.E., Peshu, N., Høyer-Hansen, G., Pedersen, B.K., Marsh, K., Ullum, H.:
Elevated plasma urokinase receptor predicts low birth weight in maternal malaria.
Parasite Immunol. 2007;29:37-46.

Høyer-Hansen, G., Lund I.K.:
Urokinase receptor variants in tissue and body fluids.
Adv. Clin. Chem. 2007; 44:65-102.

Henic, E., Sixt, M., Hansson, S., Høyer-Hansen, G., Casslén, B.:
EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator.
Gynecol.Oncol. 2006;101:28-39.

Piironen, T., Haese, A., Huland, H., Steuber, T., Christensen, I.J., Brünner, N., Danø, K., Høyer-Hansen, G., Lilja, H.:
Enhanced discrimination of benign from malignant prostatic disease by novel selective measurements of cleaved forms of urokinase receptor in serum.
Clin.Chem. 2006. 52: 838-844.

Ostrowski, S.R., Katzenstein, T.L., Pedersen, M., Høyer-Hansen, G., Gerstoft, J., Pedersen, B.K., Ullum, H.:
Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1nfected patients initiating highly active antiretroviral therapy.-i
Scand J Immunol. 2006;63:478-86.

Andersen, A.B., Law, I., Ostrowski, S.R., Lebech, A.M., Høyer-Hansen, G., Højgaard, L., Gerstoft, J., Ullum, H., Kjær, A.:
Self-reported fatigue common among optimally treated HIV patients: no correlation with cerebral FDG-PET scanning abnormalities.
Neuroimmunomodulation. 2006;13:69-75.

Ostrowski, S.R., Ravn, P., Høyer-Hansen, G., Ullum, H., Andersen, A.B.:
Elevated levels of soluble urokinase receptor in serum from mycobacteria infected patients: still looking for a marker of treatment efficacy.
Scand J Infect Dis. 2006;38:1028-32.

Usher, P.A., Thomsen, O.F., Iversen, P., Johnsen, M., Brünner, N., Høyer-Hansen, G., Andreasen, P.A., Danø, K. & Nielsen, B.S.:
Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.
Int. J. Cancer, 2005; 113:870-880.

Almasi, C.E., Høyer-Hansen, G., Christensen, I.J., Danø, K., Pappot H.:
Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue.
Lung Cancer, 2005; 48:349-355.

Ostrowski, S.R., Plomgaard,P., Fischer, C.P., Steensberg, A.S., Moller, K., Høyer-Hansen, G., Pedersen, B.K., Ullum, H.:
Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from periferal blood mononuclear cells.
Scand J Immunol. 2005, 61:197-206.

Ostrowski, S.R., Ullum, H., Goka, B.Q., Høyer-Hansen, G., Obeng-Adjei, G., Pedersen, B.K., Akanmori, B.D., Kurtzhals, J.A.:
Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome.
J. Infect. Dis. 2005; 191:1331-1341.

Danø, K., Behrendt, N., Høyer-Hansen, G., Johnsen, M., Lund, L.R., Ploug, M., Rømer, J.:
Plasminogen activation and cancer.
Throm. Haemost. 2005; 93:676-681.

Ostrowski, S.R., Piironen T, Høyer-Hansen, G., Gerstoft, J., Pedersen, B.K., Ullum, H.:
High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1nfected patients.-i
J. Acquir. Immune Defic.Syndr. 2005; 39:23-31.

Ostrowski, S.R., Piironen T, Høyer-Hansen, G., Gerstoft, J., Pedersen, B.K., Ullum, H.:
Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1nfected patients. -i
Scand. J. Immunol. 2005;61: 347-356.

Larsen, M.B., Stephens, R.W., Brünner, N., Nielsen, H.J., Engelholm, L.H., Christensen, I.J., Stetler-Stevenson, W.G., Høyer-Hansen, G.:
Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients.
Scand. J. Immunol. 2005;61: 449-460.

Nordengren, J., Pilka, R., Noskova, V., Ehinger, A., Domanski, H., Andersson, C., Hoyer-Hansen, G., Hansson, S.R., Casslen, B.:
Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
Mol Hum Reprod. 2004;10: 655-63.

Begum, F.D., Hogdall, C.K., Kjaer, S.K., Christensen, L., Blaakaer, J., Bock, J.E., Glud, E., Hoyer-Hansen, G., Ring-Larsen, H., Hogdall, E.V.:
The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Anticancer Res. 2004;24:1981-5.

Illemann, M., Hansen, U., Nielsen, H.J., Andreasen, P.A., Hoyer-Hansen, G., Lund, L.R., Dano, K., Nielsen, B.S.:
Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1.
Am J Clin Pathol. 2004;122:256-65.

Piironen, T., Laursen, B., Pass, J., List, K., Gårdsvoll, H., Ploug, M., Danø, K. and Høyer-Hansen, G.:
Specific immunoassays for the detection of intact and cleaved forms of the urokinase receptor.
Clin. Chem., 2004;50:2059-68.

Pass, J., Gårdsvoll, H., Lund, L.R., Danø, K. & Høyer-Hansen, G.: Generation of antibodies to the urokinase receptor (uPAR) by DNA immunization of uPAR knock-out mice: Membrane bound uPAR is not required for an antibody response.
Scand J Immunol. 2003, 58:298-305.

Offersen, B.V., Nielsen, B.S., Høyer-Hansen, G., Rank, F., Hamilton-Dutoit, S., Overgaard, J. & Andreasen, P.A.:
The myofibroblast is the predominant plasminogen activator inhibitor-1 expressing cell type in human breast carcinomas.
Am J Pathol. 2003,163:1887-99.

Riisbro,R., Christensen, I.J., Piironen, T., Greenall,M., Larsen,B., Stephens,R.W., Han,C., Høyer-Hansen,G., Smith,K., Brünner, N., Harris, A.L.:
Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
Clin. Cancer Res. 2002, 8:1132-1141.

Riisbro,R., Piironen, T., Brünner, N., Larsen,B., Nielsen, H.J., Stephens,R.W.& Høyer- Hansen,G.:
Measurement of soluble urokinase plasminogen activator receptor in serum.
J. Clin. Ligand Assay 2002, 25:53-56.

Høyer-Hansen, G., Pessara, U., Holm,A., Pass, J., Weidle, U., Danø, K. & Behrendt, N.:
Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
Biochem.J. 2001, 358:673-679.